On the microphone of Élisabeth Assayag in “La France strikes” this Monday, Amaury Martin, deputy director of the Institut Curie and chief of a venture devoted to feminine cancers, spoke of French know-how in most cancers analysis, referring specifically to medical trials.
France, world champion within the battle in opposition to most cancers? In any case, France is setting itself up as a benchmark on this space, assures Amaury Martin. The deputy director of the Institut Curie, visitor of Élisabeth Assayag in France is shifting this Monday, referred to as on figures for example French know-how.
“France as we speak represents 13% of world medical trials in oncology, it’s colossal. And in oncology, we now have a number of thousand molecules that are below growth,” he signifies. The physician summed up his remarks as follows: “If we needed to put a affected person in entrance of every medical trial, it will be not possible”.
However this myriad of scientific research additionally has a significant disadvantage. “In France, there are greater than 2,000 medical trials presently being recruited. Nevertheless, it is extremely troublesome for a basic oncologist, who offers with the lung, breast, prostate, colon, to know very effectively specifies medical trials regarding breast most cancers, in comparison with an professional who solely works on this most cancers all day”, explains Patricia Rigaud, founding father of the “AccessTrial.care” platform meant to help docs, generally overwhelmed by the exponential development of analysis.
“This platform will record, within the type of a database, information on medical trials presently being recruited with info on the remedies, on the modalities, what the sufferers must do, will they’ve to return to the hospital , what kind of analyzes will they be subjected to or not”, she lists. On this approach, the physician will be capable to “fill within the affected person’s profile”, through “machine studying” which can direct the practitioner “in the direction of the corresponding medical trials”.
Amaury Martin needs to reassure about information assortment
With an extra parameter: “A exact location of the place the physician is”, specifies Patricia Rigaud. An initiative that Amaury Martin welcomes, deeming this platform “important” and believing that, for a affected person, being included in a medical trial was “an actual probability”.
Confronted with the mistrust that such information assortment might arouse, the physician needs to be reassuring. “We shouldn’t be afraid of it. As a result of once we ask individuals the query ‘Do you wish to consent to your medical information being utilized by researchers’, I’m not saying commercialized or resold to 3rd events, I’m saying ‘used’, that strikes issues ahead.”